Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MARK3 | P27448 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19923722 | 0.85 | SMN1; SMN2 (0.36) | SMN1; SMN2BACE1BACE2ALDH1A1MARK3 | |
| SCHEMBL19923770 | 0.83 | SMN1; SMN2 (0.35) | SMN1; SMN2BACE1BACE2ALDH1A1MARK3 | |
| SCHEMBL19923479 | 0.82 | USP2 (0.36) | SMN1; SMN2BACE1BACE2ALDH1A1MARK3 | |
| SCHEMBL19923586 | 0.72 | — | — | |
| SCHEMBL19923718 | 0.72 | — | — | |
| SCHEMBL19923678 | 0.69 | ELANE (0.35) | SMN1; SMN2ALDH1A1MARK3LMNAUSP2 | |
| SCHEMBL19923400 | 0.68 | SMN1; SMN2 (0.36) | SMN1; SMN2BACE1BACE2ALDH1A1LMNA | |
| SCHEMBL19923786 | 0.67 | MITF (0.43) | SMN1; SMN2LMNATSHRCYP2C19TDP1 | |
| SCHEMBL19923573 | 0.67 | HTR1A (0.43) | BACE1BACE2ALDH1A1LMNATSHR | |
| SCHEMBL19923705 | 0.67 | ALDH1A1 (0.37) | BACE1BACE2ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | BRIDGESTONE CORPORATION (JP) | 2021-01-26 | — | — | US | claimed |
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2018-03-08 | — | — | US | claimed |
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | BRIDGESTONE CORPORATION (JP) | 2021-01-26 | — | — | US | disclosed |
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | PARG, HNMT, PARN | SMN1; SMN2 1697/4885BACE1 4315/4885BACE2 4642/4885 |
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | HNMT, PARG, PAM | SMN1; SMN2 1924/4885BACE1 4432/4885BACE2 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.